Life Sciences, Pharma& Healthcare

Gertjan Kuipers
Tobias Cohen Jehoram
Bertrand ter Woort
+ 38 other experts

The largest life sciences practice at a top-tier full-service firm in the Netherlands

... with a practice that spans the entire spectrum of legal services relevant to pharmaceutical companies, biotech firms and medical supply companies.

We have strength and depth across this multifaceted sector, and advise on all relevant angles of legal Life Sciences work, (from M&A and financing transactions (including IPOs of biotech firms), licensing transactions (often on a global scale), regulatory and IP strategic advice through to litigation, compliance and investigations).

Our in-house capabilities give us unique position from which to advise clients involved in Life Sciences matters which are by nature, often multidisciplinary.

Recent Matters

8 June 2021

Primavera Capital acquires Mead Johnson Business from Reckitt Benckiser Group

De Brauw assists Primavera Capital Group ("Primavera") in the acquisition of the infant formula and child nutrition business of Mead Johnson Nutrition Company ("Mead Johnson") in China from Reckitt Benckiser Group plc ("Reckitt") for an implied enterprise value of USD 2.2 billion. Reckitt will retain an 8% shareholding. Primavera and Reckitt have signed a definitive agreement to acquire Mead Johnson's Greater China infant formula and child nutrition business, including a manufacturing plant in Nijmegen, the Netherlands. Mead Johnson is a global leading infant formula and nutrition company. This acquisition is another milestone for Primavera in the consumer industry. Going forward, Primavera will fully support Mead Johnson's growth, through innovation, operational improvement, channel optimization, and digital transformation, to further enhance its positioning and growth prospects in China's infant nutrition market.Completion is, amongst other things, subject to works council consultation in the Netherlands. Subject to completing the works council consultation and the satisfaction of customary closing conditions, completion is expected in the second half of 2021.
20 May 2021

Novo Nordisk sets up EUR 5 billion EMTN programme

De Brauw advised Novo Nordisk on the establishment of its and its wholly-owned subsidiary Novo Nordisk Finance (Netherlands) B.V.'s EUR 5 billion EMTN programme. The EMTN programme provides a framework for issuance of senior unsecured notes up to an aggregated principal amount of EUR 5 billion.
5 November 2020

Viking Global Investors and General Atlantic invest in Pharvaris Series C funding round

De Brauw advised Viking Global Investors and General Atlantic on their investment in the Pharvaris Series C funding round.
Landscape debrauw paper blackstone duo high res 3

We cover a broad spectrum of Life Sciences work for pharmaceutical companies, biotech firms and medical supply companies.

On behalf of our strong client base in the food and drink industry (Unilever, PepsiCo, Danone, JDE and P&G to name but a few), we have a leading role in developments relating to food claims and the actions taken by the European Food Safety Authority (EFSA).

We are the patent litigation firm of choice for many multinationals wishing to coordinate their patent strategy throughout Europe. Our Patent Law practice members combine their strong foundation in patent and procedural law with their extensive knowledge of the economics of, and the mechanisms, in this sector.

Learn More about our patents practice

A strong Dutch full service firm with the patent department also having a focus on Life Sciences... unique in combining legal and technical thinking when developing strategies and arguments. This team is unique in their extraordinary ability to learn the subject matter in a very short time, applying it in court and turn it into victory... They are a pleasure to work with both on a professional and a personal level.

Legal 500, 2021
Legal 500, 2021